Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors

NCT04009681 is registered in ClinicalTrials.gov with Synthorx, Inc, a Sanofi company as lead sponsor.

NCT NCT04009681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04009681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
Synthorx, Inc, a Sanofi company
Phase
Phase 1/2
Overall status
Terminated
Start date
June 20, 2019
Completion date
December 2, 2025
Enrollment
175 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis